Don deBethizy Joins NOXXON Supervisory Board
Berlin, Germany and Boston, USA - 10 December 2014 - NOXXON Pharma has appointed Don deBethizy to the Company’s Supervisory Board.
In his last position as President and Chief Executive Officer of Santaris Pharma A/S, deBethizy initiated and managed the successful acquisition of the company by Roche. Previously, he was Executive Chairman of Danish bio-venture firm, Contera Pharma and oversaw its sale to Korean Bukwang Pharmaceutical. From 1997 to 2012, Dr. deBethizy was co-founder and CEO of Targacept, Inc. (NASDAQ:TRGT). He is currently on the Board of Directors of Newron Pharmaceuticals (SIX: NWRN).
Don deBethizy holds a BS degree in Biology from the University of Maryland and received a Ph.D. in Toxicology from Utah State University. He will join the current Supervisory Board of NOXXON which consists of seven industry and investor representatives.
“It is my pleasure to welcome Don to the team, as he is a highly qualified, experienced pharmaceutical company executive with significant experience of drug and technology development,” said Iain Buchanan, CEO of NOXXON Pharma. “His past experience with Santaris’ locked nucleic acid (LNA) platform and Targacept’s NNR Therapeutics are particularly relevant, and will be increasingly useful to NOXXON as we will continue to further progress and develop our pipeline.”
“NOXXON has very promising compounds in development based on its unique Spielgelmer® platform, and the company is at an exciting inflection point,” said Dr. deBethizy. “I look forward to contributing to Board discussions and helping the management with company strategy and product development.”
About NOXXON Pharma
NOXXON Pharma is a biopharmaceutical company pioneering the development of a new class of proprietary therapeutics called Spiegelmers. Spiegelmers are chemically synthesized L-stereoisomer oligonucleotide aptamers, a non-immunogenic alternative to antibodies. NOXXON has a diversified portfolio of clinical-stage Spiegelmer® therapeutics:
The Spiegelmer® platform provides the company with powerful and unique discovery capabilities, which have generated a number of additional leads under preclinical investigation. Located in Berlin, Germany, NOXXON is a well-financed mature biotech company with a strong syndicate of international investors, and approximately 55 employees.
Issued for and on behalf of Noxxon Pharma by Instinctif Partners.
For more information please contact: email@example.com